TrialNeuro-oncology2021

Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.

Christelle Dufour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.